Journal article · 2022
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Annals of the Rheumatic Diseases, 82(2), 182–188 · Published 5 October 2022 · DOI 10.1136/ard-2022-222824
In brief
“Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study” is a 2022 journal article by Léa Hoisnard and 5 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 137 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 137
- Most cited in
- 2024 (43)
- Field-weighted impact
- 17.00
- References
- 28
- Authors
- 6
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Hoisnard, L., Vegas, L. P., Dray‐Spira, R., Weill, A., Zureik, M., & Sbidian, É. (2022). Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Annals of the Rheumatic Diseases, 82(2), 182–188. https://doi.org/10.1136/ard-2022-222824
MLA 9
Hoisnard, Léa, et al. “Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.” Annals of the Rheumatic Diseases, vol. 82, no. 2, 2022, pp. 182–188. https://doi.org/10.1136/ard-2022-222824.
Chicago
Hoisnard, Léa, Laura Pina Vegas, Rosemary Dray‐Spira, Alain Weill, Mahmoud Zureik, and É. Sbidian. 2022. “Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.” Annals of the Rheumatic Diseases 82 (2): 182–188. https://doi.org/10.1136/ard-2022-222824.
Harvard
Hoisnard, L. et al. (2022) ‘Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study’, Annals of the Rheumatic Diseases, 82(2), pp. 182–188. doi:10.1136/ard-2022-222824.
IEEE
L. Hoisnard, L. P. Vegas, R. Dray‐Spira, A. Weill, M. Zureik, and É. Sbidian, “Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study,” Annals of the Rheumatic Diseases, vol. 82, no. 2, pp. 182–188, 2022, doi: 10.1136/ard-2022-222824.
BibTeX
@article{hoisnard2022risk,
title = {{Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study}},
author = {Hoisnard, Léa and Vegas, Laura Pina and Dray‐Spira, Rosemary and Weill, Alain and Zureik, Mahmoud and Sbidian, É.},
journal = {Annals of the Rheumatic Diseases},
year = {2022},
volume = {82},
number = {2},
pages = {182--188},
doi = {10.1136/ard-2022-222824},
url = {https://doi.org/10.1136/ard-2022-222824}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 2 | |
| 2023 | 34 | |
| 2024 | 43 | |
| 2025 | 38 | |
| 2026 | 20 |
Its field-weighted citation impact is 17.00: it has been cited 17.00 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- tofacitinib
- baricitinib
- adalimumab
- major adverse cardiovascular events
- venous thromboembolism
- cardiovascular safety
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Hoisnard, L., Vegas, L. P., Dray‐Spira, R., Weill, A., Zureik, M., & Sbidian, É. (2022). Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Annals of the Rheumatic Diseases, 82(2), 182–188. https://doi.org/10.1136/ard-2022-222824
How many times has this paper been cited?
137 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira, Alain Weill, Mahmoud Zureik, É. Sbidian.
What is the DOI of this paper?
10.1136/ard-2022-222824, permanently at https://doi.org/10.1136/ard-2022-222824. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.